Generex Biotechnology Corporation (GNBT), a leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced that Shreya Life Sciences Pvt. Ltd, the Company’s marketing and distribution licensee in India, has begun initial marketing activities for Generex Oral-lyn in the Indian market. Previously, Generex announced that the company has received initial approval to sell the Generex Oral-lyn drug by the Central Drugs Standard Control Organization and the Government of India.

The first effort in this marketing launch campaign will include presentations about Generex Oral-lyn’s benefits to Indian key opinion leaders and endocrinologists at closed-door meetings in Mumbai, India. Generex Oral-lyn is a portable, insulin based medicine that allows for easy self-administration, precise dosage control, and easy titration. Because India has a significant and growing number of people with diabetes, this medicine is well suited for this market.

Anna Gluskin, Generex’s President and CEO, specified, “We are very excited about the marketing launch activities taking place in India by Shreya. This demonstrates Shreya’s commitment to entering this major jurisdiction with the proper educational tools for its marketing purposes and for training amongst physicians who will be the front runners in educating patients living with diabetes. We look forward to having both teams work closely to facilitate a successful product launch in India and to follow up with continuous educational programs throughout the course of the year.”

Let us hear your thoughts below: